Traditionally, the Netherlands has an excellent reputation for its knowledge economy.
Research and development form a major part of Dutch economic activity, and many companies, such as pharmaceutical companies, profit from the Netherlands as a knowledge science centre with its favourable innovation climate. The Dutch government thinks that pharma research plays a particularly important role in innovation and therefore in the Dutch economy.
It only became clear what is at stake for this knowledge economy when the US-based pharmaceutical company MSD & Co recently announced it would move its subsidiary Organon to the US. Organon’s R&D department is currently based in the Netherlands and employs about 1,100 highly educated and specialised researchers in a specific pharmaceutical field, which would be lost if a transfer is continued.
Since this announcement, the Dutch government is alerted and now plays an important role in its attempt to keep knowledge and skills up and running in the Netherlands.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Knowledge economy
